Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Onradivir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Onradivir is an oral antiviral tablet for influenza A (flu A), developed in China by Guangdong Raynovent Biotech, where it is sold as 安睿威® (Anruiwei). It was created together with the Guangzhou National Laboratory and the First Affiliated Hospital of Guangzhou Medical University, and it is the first approved flu medicine that works on the PB2 part of the virus.
China's National Medical Products Administration (NMPA) approved it in May 2025 for:
It is a prescription infection medicine and should be used only on a doctor's advice, after flu A has been confirmed or is strongly suspected.
To multiply, the flu virus "steals" a small cap from the patient's own genetic messages and uses it to start copying itself. That job is done by the virus's polymerase, and one part of it, called PB2, grabs the cap. Onradivir blocks PB2, so the virus cannot start making new copies. Because this target is different from older flu medicines, laboratory studies showed it still worked against flu A strains that had become resistant to them.
The phase 3 trial, published in The Lancet Respiratory Medicine in 2025, enrolled adults aged 18 to 64 at 68 hospitals in China, all with fever and flu A confirmed by a rapid test within 48 hours of their first symptoms. Among the 702 people with confirmed flu A, symptoms eased in a median of 38.8 hours with onradivir compared with 63.4 hours with placebo, about a day sooner. Its results were similar to those of a standard flu medicine that was also tested in the same trial (median 42.2 hours).
Your doctor will decide whether this medicine is right for you. Flu medicines work best when they are started early, so timing matters.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Diarrhoea: this was the most common side effect. In the phase 3 trial it affected 49% of people taking onradivir compared with 23% on placebo. Most cases were mild to moderate, lasted a median of 2 days and settled without any treatment. Drink enough fluids, and tell your doctor if it is severe or does not stop.
Side effects in the trial: 67% of people on onradivir reported a side effect of some kind, compared with 55% on placebo, and the difference was mostly due to diarrhoea. Safety in pregnancy, breastfeeding and in people with serious liver or kidney disease has not been established in the published data, so discuss this with your doctor first.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Because an import takes time and flu treatment should start early, ask your doctor whether the timing still suits you. Raynovent also makes the COVID-19 tablet Leritrelvir, and for other imported antivirals see our Livtencity page.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets are kept in their sealed original box and stored as directed on the pack throughout transit. Each box of 15 tablets is one complete 5-day course. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid doctor's prescription.
Our New Delhi dispatch point keeps the last leg short, which matters for a medicine that works best when started early.
Physicians in Mumbai can send the prescription and flu test report together so the document check is quick.
Patients in Bangalore can have the 5-day course delivered to their home or clinic once the papers are verified.
We share the quote and a realistic delivery time first, so the doctor can judge whether it still fits the treatment window.
Doctors in Hyderabad can request it for a named adult patient with confirmed flu A.
Deliveries to Kolkata and the eastern states are planned to reach the patient as fast as the import allows.
Patients in Pune can use the same documented import route, with updates at each stage.
The treating doctor can send us the prescription and test result to begin the request.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating hospital.
Patients in Rajasthan can receive the tablets without travelling, as long as the import is in their own name.
We coordinate delivery for patients treated at public and private hospitals across Uttar Pradesh.
Patients across Kerala can have the course delivered to their home or hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
